| 1.17 -0.16 (-12.03%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.52 |
1-year : | 1.63 |
| Resists | First : | 1.3 |
Second : | 1.39 |
| Pivot price | 1.23 |
|||
| Supports | First : | 1.14 |
Second : | 0.95 |
| MAs | MA(5) : | 1.21 |
MA(20) : | 1.24 |
| MA(100) : | 1.36 |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26 |
D(3) : | 21.7  |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 8 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DRMA ] has closed above bottom band by 22.3%. Bollinger Bands are 56.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.2 - 1.2 | 1.2 - 1.21 |
| Close: | 1.32 - 1.33 | 1.33 - 1.34 |
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Thu, 18 Jun 2026
Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
Thu, 18 Jun 2026
Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tue, 16 Jun 2026
Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale - Stock Titan
Mon, 15 Jun 2026
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Mon, 01 Jun 2026
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
Wed, 13 May 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - newswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 24.8 (%) |
| Held by Institutions | 7.3 (%) |
| Shares Short | 97 (K) |
| Shares Short P.Month | 151 (K) |
| EPS | -4.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -103.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|